Tratnjek Larisa, Sibinovska Nadica, Kristan Katja, Kreft Mateja Erdani
Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Chair of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Pharmaceutics. 2021 Oct 20;13(11):1750. doi: 10.3390/pharmaceutics13111750.
Certain active drugs and excipients of nasal formulations may impair ciliary function and mucociliary clearance. The ciliary beat frequency (CBF) is a key parameter for determining mucociliary clearance rate, and in vitro assessments of CBF have proven to be accurate and reproducible. Since topical nasal formulations are applied with repeated doses, it is essential to elucidate their chronic, as opposed to acute, effect on mucociliary clearance and nasal mucosa. The aim of this study was to assess for the first time the ciliotoxicity and cytotoxicity of nasal sprays intended for chronic treatment (with repeated doses) using a previously designed set-up for CBF measurements. For 2 weeks, the 3D nasal MucilAir™ in vitro models were treated daily with undiluted or clinically relevant doses of mometasone nasal spray, placebo nasal spray, culture medium, or they were untreated. We demonstrated a dose-dependent and time-dependent (cumulative) effect of the nasal sprays on ciliary activity and cytotoxicity using CBF measurements and ultrastructural analysis, respectively. Our results indicate that repeated administration of clinically relevant doses of mometasone nasal spray is safe for in vivo use, which is in good agreement with a previous clinical study. Overall, our study suggests that such in vitro assays have great potential for topical nasal drug screening.
某些鼻腔制剂中的活性药物和辅料可能会损害纤毛功能和黏液纤毛清除功能。纤毛摆动频率(CBF)是确定黏液纤毛清除率的关键参数,并且CBF的体外评估已被证明是准确且可重复的。由于局部鼻腔制剂是重复给药的,因此有必要阐明它们对黏液纤毛清除和鼻黏膜的慢性(而非急性)影响。本研究的目的是首次使用先前设计的CBF测量装置,评估用于慢性治疗(重复给药)的鼻喷雾剂的纤毛毒性和细胞毒性。持续2周,每天用未稀释的或临床相关剂量的莫米松鼻喷雾剂、安慰剂鼻喷雾剂、培养基处理3D鼻腔MucilAir™体外模型,或者不进行处理。我们分别使用CBF测量和超微结构分析,证明了鼻喷雾剂对纤毛活性和细胞毒性具有剂量依赖性和时间依赖性(累积性)影响。我们的结果表明,重复给予临床相关剂量的莫米松鼻喷雾剂用于体内是安全的,这与先前的一项临床研究结果高度一致。总体而言,我们的研究表明,此类体外试验在局部鼻腔药物筛选方面具有巨大潜力。